Tag: spironolactone

1. Potassium binder therapy with patiromer can promote longer duration of spironolactone use for resistant hypertension in the setting of chronic kidney disease. Evidence Rating Level: 1 (Excellent) Spironolactone is recommended in the treatment of resistant hypertension, however there is limited data regarding its use in the setting of chronic kidney...
The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial 1. Selective serotonin reuptake inhibitors (SSRIs) are not associated with significant short-term reductions in depressive symptoms in the primary care setting, but reduce short-term anxiety and improve...
1. Use of medications to inhibit the renin-angiotensin system (RAS) following transcatheter aortic valve replacement (TAVR) for severe aortic stenosis linked with reduced cardiac mortality at 3 years. 2. RAS inhibition was also demonstrated to have a greater reduction in ventricular volume and septal hypertrophy on follow-up echocardiogram. Evidence Rating Level:...
1. In this meta-analysis of available randomized clinical trials, use of aldosterone antagonist therapy in patients with preserved ejection fraction following ST-elevation myocardial infarction (STEMI) was associated with reduction in overall mortality. 2. Use of aldosterone agonist was linked to a small increase in serum potassium and no overall difference...
Image: CC/Wiki 1. There was no significant difference in the primary composite outcome (death from cardiovascular causes, aborted cardiac arrest, and hospitalization for heart failure) between the spironolactone and placebo groups.  2. Post hoc analyses showed that spironolactone benefited patients in the Americas but not Russia or Georgia, where event rates...
Classics Series, Landmark Trials in Medicine
Image: PD 1. Adding 25 mg of spironolactone to standard therapy reduces all-cause mortality in heart failure patients with an ejection fraction <35% Original Date of Publication: September 2, 1999 Study Rundown: This landmark study supported the use of spironolactone, in addition to standard medical therapy, to reduce mortality and hospitalizations in patients...